


## Cameroun

### Region: Central Africa

#### Key information on co-financing

- Gross National Income per capita (2017): \$ 1,360
- Co-financing status (2019): Preparatory transition phase
- Country is projected to enter accelerated transition phase in 2022.



#### Immunisation financing

|  | 2013          | 2014          | 2015          | 2016          | 2017          |
|--|---------------|---------------|---------------|---------------|---------------|
| <b>Vaccines used in routine immunisation</b> |               |               |               |               |               |
| - Government expenditure                     | \$ 2,910,695  | \$ 3,185,583  | \$ 3,450,841  | \$ 4,325,811  | \$ 5,179,934  |
| - Total expenditure                          | \$ 23,754,162 | \$ 21,214,505 | \$ 35,522,064 | \$ 13,252,340 | \$ 16,878,764 |
| - Government as % of total                   | <b>12%</b>    | <b>15%</b>    | <b>10%</b>    | <b>33%</b>    | <b>31%</b>    |
| <b>Routine immunisation</b>                  |               |               |               |               |               |
| - Government expenditure                     | \$ 4,415,102  | \$ 4,947,261  | \$ 4,723,748  | \$ 4,542,974  | \$ 5,473,014  |
| - Total expenditure                          | \$ 28,391,191 | \$ 23,343,091 | \$ 46,780,189 | \$ 13,956,859 | \$ 17,171,844 |
| - Government as % of total                   | <b>16%</b>    | <b>21%</b>    | <b>10%</b>    | <b>33%</b>    | <b>32%</b>    |

Source: WHO-UNICEF Joint Reporting Form 2017

Domestic General government expenditure on health as a share of gross domestic product: **0.7%**

#### Expenditure on routine immunisation in 2017



Source: WHO National Health Accounts, 2015

#### Gavi supported vaccines

| Vaccines        | Type          | Year(s) of Gavi support | Co-financing required |
|-----------------|---------------|-------------------------|-----------------------|
| Yellow Fever    | Routine       | 2004 - present          | Yes                   |
| Tetra DTP-HepB  | Routine       | 2005 - 2009             | No                    |
| Pentavalent     | Routine       | 2008 - present          | Yes                   |
| PCV             | Routine       | 2011 - present          | Yes                   |
| Meningitis A    | Campaign      | 2011 - 2012             | No                    |
| Rotavirus       | Routine       | 2014 - present          | Yes                   |
| HPV             | Demonstration | 2014 - 2015             | No                    |
| Measles-Rubella | Campaign      | 2015                    | No                    |
| IPV             | Routine       | 2015 - present          | No                    |

#### Co-financing payments

| Year | Total amount paid by the country | Co-financed vaccines |              |        |      |
|------|----------------------------------|----------------------|--------------|--------|------|
|      |                                  | Vaccine              | Year         | Amount | Year |
| 2008 | \$ 351,000                       | -                    | Yellow Fever | -      | -    |
| 2009 | \$ 669,000                       | Penta                | Yellow Fever | -      | -    |
| 2010 | \$ 719,000                       | Penta                | Yellow Fever | -      | -    |
| 2011 | \$ 1,327,000                     | Penta                | Yellow Fever | PCV    | -    |
| 2012 | \$ 1,983,000                     | Penta                | Yellow Fever | PCV    | -    |
| 2013 | \$ 1,843,000                     | Penta                | Yellow Fever | PCV    | -    |
| 2014 | \$ 2,410,000                     | Penta                | Yellow Fever | PCV    | Rota |
| 2015 | \$ 2,631,000                     | Penta                | Yellow Fever | PCV    | Rota |
| 2016 | \$ 2,464,000                     | Penta                | Yellow Fever | PCV    | Rota |
| 2017 | \$ 1,986,000                     | Penta                | Yellow Fever | PCV    | Rota |

## Co-financing obligations for 2018


|              | Co-financing obligations<br>(in US\$) | Co-financing obligations<br>(in doses) |
|--------------|---------------------------------------|--|
| YF           | \$ 135,000                            | 113,000                                |
| Rota         | \$ 585,000                            | 282,000                                |
| PCV          | \$ 1,556,000                          | 499,800                                |
| Pentavalent  | \$ 265,000                            | 322,000                                |
| <b>Total</b> | <b>\$ 2,541,000</b>                   |  |

Note: Country is in default for 2018 co-financing payments.

## Co-financing obligations for 2019

|              | Co-financing obligations<br>(in US\$) | Co-financing obligations<br>(in doses) |
|--------------|---------------------------------------|--|
| Pentavalent  | \$ 307,000                            | 406,500                                |
| PCV          | \$ 1,258,000                          | 415,200                                |
| YF           | \$ 117,500                            | 93,300                                 |
| Rota         | \$ 520,000                            | 225,000                                |
| HPV          | \$ 574,000                            | 124,700                                |
| MR           | \$ 497,500                            | 714,000                                |
| <b>Total</b> | <b>\$ 3,274,000</b>                   |  |

## Co-financing projections for 2020 - 2024



|              | 2020                | 2021                | 2022                | 2023                | 2024                |
|--------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| HPV national | \$ 448,575          | \$ 276,926          | \$ 856,264          | \$ 545,993          | \$ 725,625          |
| Penta        | \$ 364,383          | \$ 433,124          | \$ 511,208          | \$ 729,517          | \$ 959,138          |
| PCV          | \$ 1,557,641        | \$ 1,851,532        | \$ 2,186,080        | \$ 3,119,638        | \$ 4,100,816        |
| Rota         | \$ 766,074          | \$ 910,430          | \$ 1,074,505        | \$ 1,533,029        | \$ 2,014,600        |
| YF routine   | \$ 242,839          | \$ 288,456          | \$ 340,393          | \$ 485,533          | \$ 637,914          |
| MR Routine   | \$ 572,045          | \$ 682,538          | \$ 774,295          | \$ 851,363          | \$ 931,991          |
| <b>Total</b> | <b>\$ 3,951,557</b> | <b>\$ 4,443,006</b> | <b>\$ 5,742,745</b> | <b>\$ 7,265,072</b> | <b>\$ 9,370,084</b> |

- Projections are based on Gavi's operational forecast version 16.
- These projections do not guarantee renewal of support or approval of country's application.
- Final co-financing obligations will be communicated through decision letters.